GP6 and cancer: Nonetheless, aggregation could be reversed by genetic KO of GPVI and CLEC-2, raising the potential for either combined rGal-9 and GPVI/CLEC-2 inhibitory regimens or rGal-9 intratumorally administered or cancer cell-directed modalities.